Physician profile
Sherry Ellis
NPI 1114114311
$2,545.27
in general payments reported to CMS, 2019-2025
22 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2021: $24.07 · 2022: $384 · 2023: $699 · 2024: $661 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $386.99 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $366.81 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.40 | 2019-2024 | Xifaxan |
| Abbvie INC. | $194.97 | 2019-2024 | |
| Celgene Corporation | $188.30 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $175.38 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $140.16 | 2019-2024 | Ocaliva |
| Ardelyx, INC. | $117.77 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $114.39 | 2023-2025 | |
| Lilly USA, LLC | $86.12 | 2024-2025 | Omvoh |
| Pfizer INC. | $83.15 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $71.24 | 2024-2025 | Rebyota |
| Novo Nordisk INC | $67.41 | 2021-2025 | Wegovy |
| Madrigal Pharmaceuticals | $58.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $51.54 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $37.59 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $35.89 | 2019 | |
| Aimmune Therapeutics, INC. | $23.41 | 2025 | Vowst |
| Gilead Sciences, INC. | $19.25 | 2023 | |
| Ironwood Pharmaceuticals, INC | $19.04 | 2024 | |
| Vivus LLC | $14.27 | 2024 | Pancreaze |
| Evoke Pharma, INC. | $12.85 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.